Destiny Pharma
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
-1.23K-684.03-1.05K-1.05K
Price/Sales ratio
4.49K3.47K1.66K2.06K
Earnings per Share (EPS)
Β£-0.08Β£-0.15Β£-0.1Β£-0.1

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-51.43-86.88-72.04-16.28-5.22-4.00-5.72-11.77-5.77-11.21-2.78-5.22
Price/Sales ratio
N/AN/AN/AN/AN/A61.582.48K465.54243.0976.32N/A61.58
Price/Book Value ratio
45.9570.5058.672.902.202.422.498.374.926.901.252.42
Price/Cash Flow ratio
-58.29-97.93-91.71-22.51-5.72-4.12-5.71-12.38-6.44-12.24-2.88-5.72
Price/Free Cash Flow ratio
-58.26-97.64-91.71-22.27-5.70-4.10-4.03-12.31-6.44-12.05-2.86-5.70
Price/Earnings Growth ratio
-0.562.12-3.44-0.09-0.120.48-0.620.45-1.510.34-0.11-0.12
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
N/AN/AN/AN/AN/A93.97%-35.59%90.72%92.02%99.25%N/A93.97%
Operating Profit Margin
N/AN/AN/AN/AN/A-1910.67%-52638.31%-4764.74%-5104.35%-790.08%N/AN/A
Pretax Profit Margin
N/AN/AN/AN/AN/A-1804.89%-52055.42%-4644.54%-4991.32%-775.20%N/AN/A
Net Profit Margin
N/AN/AN/AN/AN/A-1539.04%-43462.46%-3954.35%-4209.45%-680.29%N/AN/A
Effective Tax Rate
14.68%15.19%13.21%7.28%14.00%14.72%16.50%14.86%15.66%12.24%14.53%14.00%
Return on Assets
-72.51%-75.45%-74.02%-17.42%-39.56%-55.01%-39.48%-64.46%-73.93%-56.81%-41.92%-41.92%
Return On Equity
-89.34%-81.14%-81.44%-17.84%-42.15%-60.67%-43.50%-71.10%-85.28%-61.56%-47.28%-47.28%
Return on Capital Employed
-105.25%-96.30%-93.87%-16.32%-50.63%-75.32%-52.69%-85.67%-103.41%-71.49%-53.12%-53.12%
Liquidity Ratios
Current Ratio
N/AN/AN/A42.9216.2410.689.00N/AN/AN/A11.2410.68
Quick Ratio
5.3016.3612.3743.6217.4010.689.007.735.569.8810.2110.68
Cash ratio
4.3711.859.5729.498.809.377.686.004.198.3010.218.80
Days of Sales Outstanding
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Days of Inventory outstanding
N/AN/A-59.02K-48.70K-35.15KN/AN/AN/AN/AN/AN/A-35.15K
Operating Cycle
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Days of Payables Outstanding
N/AN/A15.77K26.63K15.24K10.16K15.68K6.36K5.10K23.29KN/A10.16K
Cash Conversion Cycle
N/AN/AN/AN/AN/A-10.16K-15.68K-6.36K-5.10K-23.29KN/AN/A
Debt Ratios
Debt Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.07N/A
Debt Equity Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.07N/A
Long-term Debt to Capitalization
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Total Debt to Capitalization
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Interest Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow to Debt Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Company Equity Multiplier
1.231.071.101.021.061.101.101.101.151.081.071.06
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
N/AN/AN/AN/AN/A-14.93-435.38-37.58-37.71-6.23N/AN/A
Free Cash Flow / Operating Cash Flow Ratio
1.001.0011.011.001.001.411.001.001.011.001.00
Cash Flow Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Short Term Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A